Type 2 Diabetes
Risk for major adverse CV events elevated with type 2 diabetes, cognitive impairment
Adults with type 2 diabetes and cognitive impairment are more likely to experience major adverse cardiovascular events, stroke or CV mortality compared with those without cognitive impairment, according to study findings.
Fenofibrate may lower heart failure hospitalization, CV mortality in type 2 diabetes
In a cohort of patients with type 2 diabetes treated with simvastatin, fenofibrate decreased the composite of heart failure hospitalizations or cardiovascular mortality, according to an analysis of the ACCORD Lipid trial.
Combination SGLT2, GLP-1 therapy lowers risk for adverse CV outcomes in type 2 diabetes
Combined use of an SGLT2 inhibitor and GLP-1 receptor agonist is associated with reduced odds for major adverse cardiac and cerebrovascular events and heart failure in adults with type 2 diabetes, according to study findings.
Lower birth weight tied to type 2 diabetes at younger age, lower BMI
Having a lower birth weight is associated with type 2 diabetes onset at a younger age, and those with a lower birth weight are also more likely to have a lower BMI at diagnosis, according to study findings published in Diabetic Medicine.
Primary care intervention increases prescriptions for SGLT2 inhibitors, GLP-1 agonists
A 30-minute educational intervention for primary care physicians increased prescribing rates of SGLT2 inhibitors and GLP-1 agonists among patients with type 2 diabetes and risk factors for atherosclerotic CVD, according to researchers.
Study shows early benefits of SGLT2 inhibitors in patients with heart failure
After 1 year of treatment, SGLT2 inhibitors were associated with a 32% lower risk for hospitalization due to heart failure, regardless of type 2 diabetes status, according to a new study in Annals of Internal Medicine.
Healthy plant-based diet linked to lower risk for type 2 diabetes
Metabolite profiles demonstrate that eating a healthy plant-based diet rich in whole grains, fruits, vegetables and nuts can lower one’s risk for developing type 2 diabetes, according to study findings published in Diabetologia.
FIDELITY: Real-world CV benefit of finerenone consistent regardless of ASCVD status
WASHINGTON — Finerenone was beneficial in primary and secondary prevention across the spectrum of patients with chronic kidney disease and type 2 diabetes regardless of whether they had atherosclerotic CVD, researchers reported.
Clear, evidence-based guidelines needed for NAFLD in type 2 diabetes
New findings published in Diabetic Medicine highlighted the urgent need for clear, evidence-based guidelines for managing nonalcoholic fatty liver disease in individuals with type 2 diabetes.
Top in endocrinology: Insulin price cap, 2 mg semaglutide for type 2 diabetes
The U.S. House of Representatives recently passed the Affordable Insulin Now Act, which aims to cap insulin prices at $35 per month. If approved by the Senate, the bill would go into effect January 2023.